You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

HIGHLIGHTS

EVENTS

Kedrion Biopharma joins IPOPI in supporting patients with APP PID Genius

This new APP, presented at the IPIC Congress in Dubai, will be the personal assistant to people living with PIDs

read more 

CORPORATE

Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

The product is approved for post-exposure prophylaxis against rabies infection

read more 

EVENTS

Kedrion Biopharma attends XXVI ISTH Congress in Berlin, Germany

A crowded symposium dedicated to the SIPPET Study was held on July 9th

read more 
  1. EVENTS - 23-09-2016

    Pharmaceutical digitization: how to improve patient care and engagement

    Kedrion Biopharma Advisor Prof. Albert Farrugia lectures at "The Future of Science" Conference in Venice, Italy

    read more 
  2. PLASMA & BIOTHERAPIES - 16-09-2016

    Humanitarian Factor IX donation to Afghanistan

    Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries

    read more 
  3. PLASMA & BIOTHERAPIES - 13-09-2016

    Kedrion and Kamada seek FDA approval of IgG as a post-exposure treatment

    BLA has been submitted on September 1, 2016. Companies planning for decision from FDA in mid-2017

    read more 
  4. EVENTS - 26-07-2016

    SIPPET Study was WHF 2016 World Congress highlight

    A Kedrion, Grifols and LFB supported symposium featured a lecture by Dr. Manuel Carcao

    read more 

Pages

For more information please contact: pressoffice@kedrion.com